Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06888193 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
A Phase 1 study of Hidradenitis Suppurativa and Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 10
- Study locations
NCT06888193: Recruiting Phase 1 study of Hidradenitis Suppurativa and Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
NCT06888193 is a Phase 1 study of Hidradenitis Suppurativa and Psoriatic Arthritis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 20 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06888193, a Phase 1 study of Hidradenitis Suppurativa and Psoriatic Arthritis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 10
- Study locations
Study Summary
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
Primary Outcome
Breast milk samples will be collected predose on Day 1.
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (10)
Other
- Up0122 202 - Calgary
- Up0122 201 - Vancouver
- Up0122 303 - Herne
- Up0122 501 - Barcelona
- Up0122 502 - Barcelona
- Up0122 602 - Lausanne
- Up0122 601 - Sankt Gallen
California
- Up0122 105 - Santa Monica
Florida
- Up0122 103 - South Miami
North Carolina
- Up0122 102 - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2027-05-03 |
| Phase | Phase 1 |
What NCT06888193 shows while recruiting
NCT06888193 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT06888193 lists 10 locations in 4 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06888193 about?
NCT06888193 is a clinical study titled "A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)". Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
What is the current status of trial NCT06888193?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-11-05. Estimated completion is 2027-05-03.
What conditions does trial NCT06888193 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa, Psoriatic Arthritis, Axial Spondyloarthritis, Moderate to Severe Plaque Psoriasis.
What interventions are being tested in trial NCT06888193?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT06888193?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06888193 being conducted?
This trial has 10 study locations across California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06888193's enrollment target sits among peer trials
20 41st of 52 higher than 9 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
-
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
ACTIVE NOT RECRUITING · Phase 1
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI